 | | Vol. 22.13 – 12 April, 2021 |
| |
|
|
| Scientists identified the nuclear xenobiotic receptor CAR as a regulator of MDR1 expression in T cells that could safeguard against bile acid toxicity and inflammation in the mouse small intestine.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors extensively characterized the pre manufacture T-cells of 71 patients with B-cell malignancies on trial to receive anti-CD19 CAR T-cell therapy.
[Cancer Discovery] |
|
|
|
| Investigators describe how to humanize immunodeficient mice with hematopoietic stem cells and precondition and administer the vector stocks.
[Nature Protocols] |
|
|
|
| Scientists tested the safety and efficacy of chimeric antigen receptor T cell therapy in refractory/relapsed acute myeloid leukemia.
[Clinical Cancer Research] |
|
|
|
| The authors developed computational pipelines to assess single-cell genomics and transcriptomics datasets from OCT4 CRISPR-Cas9–targeted and control human preimplantation embryos
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Researchers aimed to develop a new CD22-CAR construct with low immunogenicity and potent activity for treating B acute lymphoblastic leukemia (B-ALL) patients who failed from prior CD22-CAR T cell therapies.
[Blood Cancer Journal] |
|
|
|
| Scientists evaluated the long-term effects of human induced pluripotent stem cell-derived retinal pigment epithelial and photoreceptor cell transplantation in Pde6b knockout rats to study retinitis pigmentosa.
[Experimental & Molecular Medicine] |
|
|
|
| Investigators explored the occurrence and prognosis of diffuse alveolar hemorrhage after allogeneic hematopoietic stem cell transplantation.
[Bone Marrow Transplantation] |
|
|
|
| Using murine xenograft models, investigators demonstrated that, despite widespread expression of ErbB receptors in healthy organs, the approach provided anti-tumor efficacy without off-tumor toxicity.
[Cell Reports Medicine] |
|
|
|
|
| Scientists discuss recent innovations in CAR-T cell engineering to improve clinical efficacy in both hematological malignancy and solid tumors and strategies to overcome limitations of CAR-T cell therapy in both hematological malignancy and solid tumors.
[Blood Cancer Journal] |
|
|
|
| The authors review various therapeutic strategies that use CRISPR/Cas to correct or bypass Duchenne muscular dystrophy mutations.
[Molecular Therapy-Methods & Clinical Development] |
|
|
|
|
| City of Hope and CytoImmune Therapeutics Inc. have entered into worldwide exclusive license agreements to several patent applications related to methods to generate large numbers of fully functional natural killer (NK) cells derived from umbilical cord blood and compositions of chimeric receptors (CAR) for targeting NK cells to tumors.
[CytoImmune Therapeutics, Inc. (BusinessWire, Inc)] |
|
|
|
|
| April 19 – 23, 2021
Virtual |
|
|
|
|
|
| | Rutgers University – New Brunswick, New Jersey, United States |
|
|
|
| | NIH National Institute of Allergy and Infectious Diseases – Bethesda, Maryland, United States |
|
|
|
| | The University of Iowa – Iowa City, Iowa, United States |
|
|
|
| | University of Washington – Seattle, Washington, United States |
|
|
|
| | Gladstone Institute – San Francisco, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
